Angiotensin III (Human, Mouse) Mechanisms, Clinical Applicat

Angiotensin III (Human, Mouse): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Angiotensin III (Ang III), a heptapeptide derived from the renin-angiotensin system (RAS), plays a pivotal role in cardiovascular and renal physiology. Structurally, Ang III is formed by the enzymatic cleavage of Angiotensin II (Ang II), resulting in the peptide sequence Arg-Val-Tyr-Ile-His-Pro-Phe for both human and mouse homologs (Kono et al., 2014, Hypertension Research). Unlike its precursor Ang II, Ang III exhibits unique receptor affinities and biological activities, particularly influencing blood pressure regulation, aldosterone secretion, and sodium homeostasis.

The mechanism of action of Ang III involves binding to angiotensin receptors, primarily the angiotensin type 1 (AT1) and type 2 (AT2) receptors. While Ang II is the principal agonist for these receptors, Ang III demonstrates comparable affinity for AT1 and a higher relative affinity for AT2, especially in the brain and renal tissues (Padia & Carey, 2013, Hypertension). This differential receptor interaction underlies the distinct physiological and pathophysiological roles of Ang III, making it a subject of significant interest in cardiovascular, renal, and neuroendocrine research.

Clinical Value and Applications
Angiotensin III has emerged as a critical effector peptide in the RAS, with implications for several clinical domains:

1. **Hypertension and Blood Pressure Regulation:** Ang III is recognized for its potent vasoconstrictive properties, contributing to the maintenance of arterial blood pressure. In certain experimental models, Ang III has been shown to sustain hypertensive states even in the absence of Ang II, highlighting its compensatory role (Padia & Carey, 2013).

2. **Aldosterone Secretion:** Ang III is a potent stimulator of aldosterone release from the adrenal cortex, often surpassing Ang II in this function, particularly in primate and human tissues (Kono et al., 2014). This property is relevant for disorders of mineralocorticoid excess and sodium retention.

3. **Renal Sodium Handling:** Through its actions on AT1 and AT2 receptors in the kidney, Ang III modulates sodium reabsorption and natriuresis, impacting fluid balance and blood pressure homeostasis (Padia & Carey, 2013).

4. **Central Nervous System Effects:** Ang III exerts significant effects on central blood pressure regulation and thirst mechanisms, acting within the hypothalamus and other brain regions (Wright et al., 2013, Frontiers in Endocrinology).

5. **Experimental and Translational Research:** Synthetic Ang III (human, mouse) peptides are widely used in preclinical studies to dissect RAS pathways, evaluate receptor pharmacology, and develop novel antihypertensive agents.

[Related: rock inhibitor stem cell] Key Challenges and Pain Points Addressed
Current antihypertensive therapies primarily target Ang II or its receptors, yet several challenges persist:

- **Incomplete Blood Pressure Control:** Some patients exhibit resistance to conventional RAS blockade, possibly due to compensatory upregulation of Ang III or alternative RAS pathways (Padia & Carey, 2013).

- **Aldosterone Escape:** Despite AT1 receptor antagonism, aldosterone levels may remain elevated, a phenomenon termed "aldosterone escape," in which Ang III is implicated as a key mediator (Kono et al., 2014).

- **Renal and Central Effects:** Ang III’s distinct actions in the kidney and brain are not fully addressed by current therapies, limiting efficacy in salt-sensitive hypertension and neurogenic hypertension.

- **Research Gaps:** The precise physiological and pathological roles of Ang III remain incompletely understood, necessitating the availability of high-purity, species-specific peptides for mechanistic studies.

By providing synthetic Ang III (human, mouse), researchers can directly investigate these pathways, develop targeted interventions, and refine therapeutic strategies for resistant hypertension, heart failure, and related disorders.

Literature Review
A growing body of research underscores the significance of Ang III in cardiovascular and renal physiology:

1. **Padia & Carey (2013, Hypertension):** This review delineates the role of Ang III as a major effector peptide in the kidney, mediating natriuresis and aldosterone secretion via AT2 receptor activation. The authors highlight the therapeutic potential of targeting Ang III-AT2 pathways in salt-sensitive hypertension.

2. **Kono et al. (2014, Hypertension Research):** The study demonstrates that Ang III, rather than Ang II, is the predominant stimulus for aldosterone secretion in human adrenal tissue. This finding challenges the traditional paradigm and suggests new targets for mineralocorticoid-related disorders.

3. **Wright et al. (2013, Frontiers in Endocrinology):** The authors review the central actions of Ang III, noting its potent pressor and dipsogenic effects in the hypothalamus. The paper discusses the implications for neurogenic hypertension and the potential for central RAS modulation.

4. **Zini et al. (1996, European Journal of Pharmacology):** This experimental study compares the pressor and aldosterone-releasing effects of Ang II and Ang III in rats, revealing that Ang III can sustain blood pressure and aldosterone levels independently of Ang II.

5. **Chai et al. (2008, Hypertension):** The research investigates the natriuretic response to Ang III in AT2 receptor-deficient mice, confirming the critical role of AT2 in mediating Ang III-induced natriuresis.

6. **Reaux et al. (2001, Proceedings of the National Academy of Sciences):** The study identifies aminopeptidase A as the key enzyme converting Ang II to Ang III in the brain, implicating this pathway in central blood pressure regulation.

7. **Feng et al. (2008, American Journal of Physiology):** This paper explores the renal hemodynamic effects of Ang III in isolated perfused kidneys, demonstrating its role in modulating glomerular filtration and renal blood flow.

[Related: bleomycin price] Experimental Data and Results
Preclinical and translational studies utilizing synthetic Ang III (human, mouse) have yielded several important findings:

- **Aldosterone Secretion:** Kono et al. (2014) reported that Ang III stimulates aldosterone release from human adrenal zona glomerulosa cells with greater potency than Ang II, particularly in the presence of angiotensinase inhibitors. This effect is mediated by both AT1 and AT2 receptors.

- **Blood Pressure Regulation:** Zini et al. (1996) demonstrated that intravenous administration of Ang III in rats produces sustained increases in arterial pressure, comparable to Ang II, but with a longer duration of action. The pressor response is attenuated by AT1 receptor antagonists, confirming receptor-mediated effects.

- **Renal Effects:** Chai et al. (2008) showed that Ang III induces natriuresis in wild-type mice but not in AT2 receptor knockout mice, establishing the necessity of AT2 signaling for this response. Similarly, Feng et al. (2008) observed that Ang III increases renal blood flow and glomerular filtration rate in isolated kidney preparations.

- **Central Actions:** Reaux et al. (2001) found that microinjection of Ang III into the hypothalamic paraventricular nucleus elevates blood pressure and stimulates vasopressin release, effects blocked by AT1 and AT2 antagonists.

These experimental results validate the biological activity of synthetic Ang III and its utility in dissecting RAS-mediated mechanisms in both human and mouse models.

Usage Guidelines and Best Practices
For research applications, synthetic Angiotensin III (human, mouse) peptides should be handled and administered according to established protocols:

- **Preparation:** Reconstitute lyophilized Ang III in sterile, distilled water or appropriate buffer (e.g., phosphate-buffered saline) to achieve the desired concentration. Avoid repeated freeze-thaw cycles to maintain peptide integrity.

- **Dosage:** Experimental dosages vary depending on the model system and research objective. In rodent studies, typical intravenous or intracerebral doses range from 0.1 to 10 nmol/kg, with titration based on observed physiological responses (Zini et al., 1996; Reaux et al., 2001).

- **Administration:** For in vivo studies, Ang III can be administered via intravenous, intraperitoneal, or intracerebral routes. In vitro, it is commonly applied to isolated tissue preparations or cultured cells.

- **Controls:** Include appropriate controls such as vehicle-treated, Ang II-treated, and receptor antagonist-treated groups to delineate specific effects.

- **Species Specificity:** Use human or mouse Ang III as appropriate for the experimental species to ensure receptor compatibility and physiological relevance.

- **Storage:** [Related: MCC950 sodium] Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 62 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11463420